StreetInsider.com News Articles

Form 4 Absci Corp For: May 31 Filed by: Jonasson Zachariah

Mon, 01 Jun 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260601/26585452.html

Form 4 Absci Corp For: May 31 Filed by: Jonasson Zachariah

Mon, 01 Jun 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260601/26585452.html

BTIG Starts Absci Corp. (ABSI) at Buy

Thu, 28 May 2026 06:05:34 -0400

BTIG analyst Kambiz Yazdi initiates coverage on Absci Corp. (NASDAQ: ABSI) with a Buy rating and a price target of $9.00.

The analyst comments "Absci Corporation is a clinical-stage biotechnology company that integrates generative AI and high-throughput biology to design novel protein therapeutics. The company's proprietary platform creates and optimizes antibodies, underpinning a pipeline of internal and partnered drug candidates. Lead internal candidate ABS-201 (PRLR antagonist) is in Ph1/2a for androgenetic alopecia (AGA) and advancing into endometriosis. We project $2.2B in peak sales for ABS-201 across AGA and endometriosis and initiate at BUY with a $9 price target."

For an analyst ratings

BTIG Starts Absci Corp. (ABSI) at Buy

Thu, 28 May 2026 06:05:34 -0400

BTIG analyst Kambiz Yazdi initiates coverage on Absci Corp. (NASDAQ: ABSI) with a Buy rating and a price target of $9.00.

For an analyst ratings

Absci to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 08:00:00 -0400

VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:

2026 Jefferies Global Healthcare Conference (New York, NY)
Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time

Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)
Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time

Interested parties may access live

Absci to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 08:00:00 -0400

2026 Jefferies Global Healthcare Conference (New York, NY)
Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time

Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)
Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time

Interested parties may access live

Absci to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 08:00:00 -0400

2026 Jefferies Global Healthcare Conference (New York, NY)
Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time

Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)
Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time

Interested parties may access live

Absci to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 08:00:00 -0400

2026 Jefferies Global Healthcare Conference (New York, NY)
Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time

Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)
Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time

Interested parties may access live

Absci Corp. (ABSI) PT Lowered to $4.10 at Morgan Stanley

Thu, 14 May 2026 08:52:05 -0400

Morgan Stanley analyst Sean Laaman lowered the price target on Absci Corp. (NASDAQ: ABSI) to $4.10 (from $4.20) while maintaining a Equalweight rating.

Form 4 Absci Corp For: May 13 Filed by: Pangalos Menelas N

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485883.html

Form 4 Absci Corp For: May 13 Filed by: Pangalos Menelas N

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485883.html

Absci Corp. (ABSI) PT Raised to $11 at Jones Trading

Tue, 12 May 2026 16:57:24 -0400

Jones Trading analyst Debanjana Chatterjee raised the price target on Absci Corp. (NASDAQ: ABSI) to $11.00 (from $9.00) while maintaining a Buy rating.

Absci Corp. (ABSI) PT Raised to $11 at Truist Securities

Fri, 08 May 2026 07:18:33 -0400

Truist Securities analyst Robyn Karnauskas raised the price target on Absci Corp. (NASDAQ: ABSI) to $11.00 (from $9.00) while maintaining a Buy rating.

Form 10-Q Absci Corp For: Mar 31

Thu, 07 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26454056.html

Form 10-Q Absci Corp For: Mar 31

Thu, 07 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26454056.html

Form 8-K Absci Corp For: May 07

Thu, 07 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260507/26453929.html

Form 8-K Absci Corp For: May 07

Thu, 07 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260507/26453929.html

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Thu, 07 May 2026 16:05:00 -0400

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data

Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval

Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial

Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline

VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Thu, 07 May 2026 16:05:00 -0400

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data

Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval

Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial

Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 04 May 2026 20:11:00 -0400

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 04 May 2026 20:11:00 -0400

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 04 May 2026 20:11:00 -0400

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 04 May 2026 20:11:00 -0400

H.C. Wainwright Reiterates Buy Rating on Absci Corp. (ABSI)

Tue, 28 Apr 2026 06:44:50 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $8.00 price target on Absci Corp. (NASDAQ: ABSI).

The analyst commented: "On April 27, Veradermics (MANE; not rated) reported Phase 2/3 topline data from Study 302 evaluating VDPHL01, an extended-release oral minoxidil, being evaluated in pattern hair loss (PHL). Study 302 met its primary regulatory endpoint of placebo-adjusted Target Area Hair Count (TAHC), with the once-daily and twice-daily arms delivered an unadjusted increase from baseline of 30–33 hairs/cm² (placebo-adjusted: 23–26 hairs/cm²) at six months, statistically significant at both doses (p<0.0001). The strong market reaction resulting in a gain of 47.6% for

Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Thu, 23 Apr 2026 16:05:00 -0400

VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor